Study Reaffirms Safety of Acetaminophen
Data Show Recommended Daily Doses of Acetaminophen
Not Linked to Liver Injury in Alcoholics
DENVER, Oct. 7 /PRNewswire/ -- Results of a study published in today's issue of the American Medical Association's "Archives of Internal Medicine"* show repeated use of the maximum recommended daily dose of acetaminophen, the medicine in Tylenol(R), is not associated with evidence of liver (hepatic) injury -- even in high-risk patients. Physician researchers at Denver Health's Rocky Mountain Poison & Drug Center, who serve on the faculty of the University of Colorado Health Sciences Center (UCHSC) in Denver, conducted the randomized, double-blind, placebo-controlled trial to determine the effects of therapeutic doses of acetaminophen on the liver of 201 alcoholic patients immediately following cessation of alcohol use. "Our study is the largest prospective study of its kind to date," says lead researcher Edwin K. Kuffner, MD, Toxicologist, Rocky Mountain Poison and Drug Center, Denver. "We found that therapeutic doses of acetaminophen are safe, even in high-risk populations such as alcoholics," Dr. Kuffner notes that in recent years, reports based on retrospective reviews of existing data have suggested that alcoholic patients may be at risk of liver injury after taking recommended doses of acetaminophen "All of these retrospective reviews contained serious flaws," says Dr. Kuffner. "Either they relied on the patient's history to estimate the dose of acetaminophen ingested or failed to consider other potential causes of liver injury." Dr. Kuffner adds that the researchers at UCHSC designed their study to avoid these pitfalls. Patients in the acetaminophen group received 4000 mg (the maximum recommended daily dosage) orally, for two consecutive days. Liver tests were administered during the subsequent two days to detect small changes in liver enzyme levels. Acetaminophen was not administered until alcohol had been eliminated from each patient. Despite the generally recognized weaknesses of retrospective data, some authors have continued to use these retrospective reviews to recommend that alcoholic patients reduce doses of acetaminophen or avoid the drug. Richard C. Dart, MD, PhD, study co-author, and Director, Rocky Mountain Poison and Drug Center, Denver, cautions that such assertions create confusion about appropriate treatment. "In my opinion, acetaminophen is the safest over-the-counter pain reliever available," says Dr. Dart. "The other choices a patient has include aspirin, ibuprofen, and other nonsteroidal anti-inflammatory agents (NSAIDs). Even at therapeutic doses, the NSAIDs have much more severe risk profiles than acetaminophen and are much more difficult to treat in overdose." Dr. Dart adds that clinical data indicate that aspirin in particular can cause stomach irritation and bleeding, even in the absence of alcohol; however the risk of serious stomach bleeding associated with aspirin is at least double in the presence of alcohol. According to Dr. Dart, further research is needed to explore the safety of over-the-counter pain relievers in alcoholics and other high-risk patients. This research was supported by a grant from McNeil Consumer Healthcare, maker of Tylenol(R). Denver Health integrates acute hospital and emergency care with public and community health and includes Denver Health Medical Center, Denver's 911 system, Denver Paramedic Division, 11 family health centers, 12 school-based health centers, Rocky Mountain Poison and Drug Center, Correctional Care, Denver CARES, the Public Health Department, Denver Health Foundation and Denver Health Medical Plan. * Kuffner, EK, Dart RC, Bogdan, GM, et al: Effect of Maximal Daily Doses of Acetaminophen on the Liver of Alcoholic Patients: A Randomized Double Blind Controlled Trial. Archives of Internal Medicine October 2001 MAKE YOUR OPINION COUNT - Click Here http://tbutton.prnewswire.com/prn/11690X80896928
SOURCE Denver Health
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.